Generic drug
Montelukast price, strengths & recalls
Generic of Singulair
Pharmacies pay $1.30 for 30 tablets of Montelukast 10 mg tablet this week, and from $1.30 to $23.39 across its 4 priced strengths and forms. 35 manufacturers make it. It is in shortage (being discontinued). 2 recalls are ongoing. Its official label last changed on July 30, 2026.
Being discontinued2 open recallsGeneric- Fair cash price
- $12.00
- Strengths
- 4
- Makers
- 35
- Updated
- Nov 11
Montelukast price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 4 mg chewable tablet | $0.0784 | $2.35 / 30 tablets |
| 5 mg chewable tablet | $0.0723 | $2.17 / 30 tablets |
| 4 mg oral granules | $0.7796 | $23.39 / 30 granules |
| 10 mg tablet | $0.0432 | $1.30 / 30 tablets |
The lowest cost per tablet is 10 mg tablet at $0.0432. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of montelukast
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 14 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Montelukast
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use MONTELUKAST SODIUM safely and effectively. See full prescribing information for MONTELUKAST SODIUM. MONTELUKAST SODIUM tablets, for oral use MONTELUKAST SODIUM chewable tablets, for oral use MONTELUKAST SODIUM oral granules Initial U.S. Approval: 1998
WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
See full prescribing information for complete boxed warning.
Serious neuropsychiatric events have been reported in patients taking montelukast sodium (5.1).
Discuss benefits and risks of montelukast sodium with patients and caregivers (5.1).
Monitor for neuropsychiatric symptoms in patients taking montelukast sodium (5.1).
Discontinue montelukast sodium immediately if neuropsychiatric symptoms occur (5.1).
Because the benefits of montelukast sodium may not outweigh the potential risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies (1.3, 5.1)
WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS
Serious neuropsychiatric (NP) events have been reported with the use of montelukast sodium. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with montelukast sodium use are currently not well understood [see Warnings and Precautions(5.1)].
Because of the risk of NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of montelukast sodium for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3)]. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing montelukast sodium.
Discuss the benefits and risks of montelukast sodium with patients and caregivers when prescribing montelukast sodium. Advise patients and/or caregivers to be alert for changes in behavior or new NP symptoms when taking montelukast sodium. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue montelukast sodium and contact a healthcare provider immediately [see Warnings and Precautions (5.1)].
Recent major changes (as listed on the label)
RECENT MAJOR CHANGES
Boxed Warning 04/2020
Indications and Usage (1.3. 1.4) 02/2021
Dosage and Administration, (2.1, 2.2, 2.3, 2.4) 02/2021
Warnings and Precautions (5.1, 5.6) 02/2021
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020829 · Organon
- First approved
- February 20, 1998 (28 years ago)
- Latest approved change
- February 22, 2021
- Approved label
- PDF, Feb 24, 2021
- Generic makers
- 23 approved generic applications on the market
Montelukast questions
How much does montelukast cost without insurance?
Pharmacies pay about $1.30 for 30 tablets of montelukast 10 mg tablet ($0.0432 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $12.00. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of montelukast?
Montelukast is sold as Singulair. The generic has the same active ingredient and usually costs far less.
Is montelukast in shortage?
Yes. 1 product is listed as in shortage or being discontinued (being discontinued). See which ones.
Has montelukast been recalled?
14 recalls on record, 2 ongoing. Recalls name specific lots - check yours.
When did the montelukast label last change?
The official label was last updated on July 30, 2026 (version 24). See what changed.
Talk about montelukast
No comments yet. Questions, tips, what worked for you - start the conversation.